ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience (NASDAQ:ZIVO) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.

Which has more risk and volatility, ZIVO or NGNE?

ZIVO Bioscience has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, Neurogene has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Does the media refer more to ZIVO or NGNE?

In the previous week, Neurogene had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for ZIVO Bioscience. Neurogene's average media sentiment score of 1.21 beat ZIVO Bioscience's score of 0.00 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurogene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ZIVO or NGNE more profitable?

ZIVO Bioscience's return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
Neurogene	N/A	-32.81%	-27.96%

Which has preferable valuation and earnings, ZIVO or NGNE?

ZIVO Bioscience has higher earnings, but lower revenue than Neurogene. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	4,322.27	-$7.78M	-$4.28	-4.21
Neurogene	$925K	237.44	-$36.32M	-$4.27	-3.61

Do analysts recommend ZIVO or NGNE?

Neurogene has a consensus price target of $47.20, suggesting a potential upside of 206.49%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neurogene	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the MarketBeat Community prefer ZIVO or NGNE?

ZIVO Bioscience received 70 more outperform votes than Neurogene when rated by MarketBeat users. However, 96.67% of users gave Neurogene an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote.

Company	Underperform	Outperform
ZIVO Bioscience	Outperform Votes 99 60.74%	Underperform Votes 64 39.26%
Neurogene	Outperform Votes 29 96.67%	Underperform Votes 1 3.33%

Do institutionals and insiders hold more shares of ZIVO or NGNE?

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by company insiders. Comparatively, 9.9% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Neurogene beats ZIVO Bioscience on 13 of the 18 factors compared between the two stocks.